Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Francesca Casaluce

Showing results (21-30 of 34) with videos related to

Pageof 4
Sort By:
Current Pharmaceutical Design|October 22, 2013
Irreversible EGFR inhibitors in the treatment of advanced NSCLCPaolo Maione, Antonio Rossi, Marianna Bareschino, et al.
Expert Opinion on Pharmacotherapy|January 10, 2017
Developments in pharmacotherapy for treating metastatic non-small cell lung cancerAntonio Rossi, Paola Claudia Sacco, Giuseppe Santabarbara, et al.
Expert Review of Clinical Pharmacology|December 19, 2015
Endocrinopathies induced by immune-checkpoint inhibitors in advanced non-small cell lung cancerEmanuela Rossi, Assunta Sgambato, Giovanni De Chiara, et al.
Current Clinical Pharmacology|May 4, 2016
Resistance to Crizotinib in Advanced Non-Small Cell Lung Cancer (NSCLC) with ALK Rearrangement: Mechanisms, Treatment Strategies and New Targeted TherapiesFrancesca Casaluce, Assunta Sgambato, Paola Claudia Sacco, et al.
Expert Review of Anticancer Therapy|October 17, 2015
Current challenges of lung cancer care in an aging populationPaola Claudia Sacco, Francesca Casaluce, Assunta Sgambato, et al.
Targeted Oncology|January 18, 2013
ALK inhibitors: a new targeted therapy in the treatment of advanced NSCLCFrancesca Casaluce, Assunta Sgambato, Paolo Maione, et al.
Current Pharmaceutical Design|February 12, 2013
New molecular targets in the treatment of NSCLCClorinda Schettino, Maria Anna Bareschino, Paola Claudia Sacco, et al.
Expert Opinion on Drug Safety|March 10, 2017
The safety of second-line treatment options for non-small cell lung cancerAntonio Rossi, Paolo Maione, Giuseppe Santabarbara, et al.
International Journal of Oncology|June 4, 2014
ALK inhibitors and advanced non-small cell lung cancer (review)Antonio Rossi, Paolo Maione, Paola Claudia Sacco, et al.
Frontiers in Bioscience (Landmark Edition)|January 7, 2014
The PI3k inhibitors: new hopes in the battle against advanced NSCLCPaola Claudia Sacco, Paolo Maione, Antonio Rossi, et al.
Pageof 4

Showing results (21-30 of 34) with videos related to

Sort By:
Pageof 4
Current Pharmaceutical Design|October 22, 2013
Irreversible EGFR inhibitors in the treatment of advanced NSCLCPaolo Maione, Antonio Rossi, Marianna Bareschino, et al.
Expert Opinion on Pharmacotherapy|January 10, 2017
Developments in pharmacotherapy for treating metastatic non-small cell lung cancerAntonio Rossi, Paola Claudia Sacco, Giuseppe Santabarbara, et al.
Expert Review of Clinical Pharmacology|December 19, 2015
Endocrinopathies induced by immune-checkpoint inhibitors in advanced non-small cell lung cancerEmanuela Rossi, Assunta Sgambato, Giovanni De Chiara, et al.
Current Clinical Pharmacology|May 4, 2016
Resistance to Crizotinib in Advanced Non-Small Cell Lung Cancer (NSCLC) with ALK Rearrangement: Mechanisms, Treatment Strategies and New Targeted TherapiesFrancesca Casaluce, Assunta Sgambato, Paola Claudia Sacco, et al.
Expert Review of Anticancer Therapy|October 17, 2015
Current challenges of lung cancer care in an aging populationPaola Claudia Sacco, Francesca Casaluce, Assunta Sgambato, et al.
Targeted Oncology|January 18, 2013
ALK inhibitors: a new targeted therapy in the treatment of advanced NSCLCFrancesca Casaluce, Assunta Sgambato, Paolo Maione, et al.
Current Pharmaceutical Design|February 12, 2013
New molecular targets in the treatment of NSCLCClorinda Schettino, Maria Anna Bareschino, Paola Claudia Sacco, et al.
Expert Opinion on Drug Safety|March 10, 2017
The safety of second-line treatment options for non-small cell lung cancerAntonio Rossi, Paolo Maione, Giuseppe Santabarbara, et al.
International Journal of Oncology|June 4, 2014
ALK inhibitors and advanced non-small cell lung cancer (review)Antonio Rossi, Paolo Maione, Paola Claudia Sacco, et al.
Frontiers in Bioscience (Landmark Edition)|January 7, 2014
The PI3k inhibitors: new hopes in the battle against advanced NSCLCPaola Claudia Sacco, Paolo Maione, Antonio Rossi, et al.
Pageof 4